Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.